Skip to main content
Download PDF

Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel–Trenaunay syndrome in an Asian population

Orphanet Journal of Rare Diseases volume 18, Article number: 270 (2023) Cite this article

This article has been updated

Abstract

Background

Klippel–Trenaunay syndrome (KTS) is a rare slow-flow combined vascular malformation with limb hypertrophy. KTS is thought to lie on the PIK3CA-related overgrowth spectrum, but reports are limited. PIK3CA encodes p110α, a catalytic subunit of phosphatidylinositol 3-kinase (PI3K) that plays an essential role in the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway. We aimed to demonstrate the clinical utility of targeted next-generation sequencing (NGS) in identifying PIK3CA mosaicism in archival formalin-fixed paraffin-embedded (FFPE) tissues from patients with KTS.

Results

Participants were 9 female and 5 male patients with KTS diagnosed as capillaro-venous malformation (CVM) or capillaro-lymphatico-venous malformation (CLVM). Median age at resection was 14 years (range, 5–57 years). Median archival period before DNA extraction from FFPE tissues was 5.4 years (range, 3–7 years). NGS-based sequencing of PIK3CA achieved an amplicon mean coverage of 119,000x. PIK3CA missense mutations were found in 12 of 14 patients (85.7%; 6/8 CVM and 6/6 CLVM), with 8 patients showing the hotspot variants E542K, E545K, H1047R, and H1047L. The non-hotspot PIK3CA variants C420R, Q546K, and Q546R were identified in 4 patients. Overall, the mean variant allele frequency for identified PIK3CA variants was 6.9% (range, 1.6–17.4%). All patients with geographic capillary malformation, histopathological lymphatic malformation or macrodactyly of the foot had PIK3CA variants. No genotype–phenotype association between hotspot and non-hotspot PIK3CA variants was found. Histologically, the vessels and adipose tissues of the lesions showed phosphorylation of the proteins in the PI3K/AKT/mTOR signaling pathway, including p-AKT, p-mTOR, and p-4EBP1.

Conclusions

The PI3K/AKT/mTOR pathway in mesenchymal tissues was activated in patients with KTS. Amplicon-based targeted NGS could identify low-level mosaicism from low-input DNA extracted from FFPE tissues, potentially providing a diagnostic option for personalized medicine with inhibitors of the PI3K/AKT/mTOR signaling pathway.

Background

Klippel–Trenaunay syndrome (KTS, [MIM 149,000]) is a slow-flow combined vascular malformation with a characteristic triad of symptoms: capillary malformation (CM), limb hypertrophy, and venous malformation (VM) with or without lymphatic malformation (LM) [1, 2]. From 2012 onward, several studies have reported on PIK3CA variants found in KTS. Kurek et al. screened DNA extracted from lesional tissue in 3 of 15 patients with KTS and found PIK3CA variants [3]. Luks et al. reported that up to 90% of patients with KTS have PIK3CA variants in pathological lesions. Accordingly, KTS is thought to lie on the PIK3CA-related overgrowth spectrum (PROS) [4, 5], but reports are limited [3, 6,7,8,9] and genetic differences among races are unknown.

PIK3CA encodes p110α, a catalytic subunit of phosphatidylinositol 3-kinase (PI3K) that plays a role in cellular processes such as proliferation, motility, invasion, and death through its involvement in the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway [10]. Moreover, p110α is required for endothelial cell migration during angiogenesis [11, 12], and its aberrant activation has been associated with the development of vascular malformations [13, 14]. Activation of PI3K leads to phosphorylation of AKT followed by mTOR and its downstream targets, including eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) [15].

The activation of mutations in PIK3CA is reported to play a role in many human cancers [16]. Of the PIK3CA variants, more than 80% are found at three hotspots: the glutamates E542 and E545, located in the helical domain of exon 10, and the histidine H1047, located in the kinase domain of exon 21 [17]. These three mutations exert the strongest effect on downstream signaling and enzymatic activation [17]. In patients with KTS as well, E542K, E545K, H1047R, and H1047L are the most frequent (i.e., hotspot) variants [3, 6, 8, 9].

These somatic gain-of-function variants, which arise in the postzygotic stage during embryonic development, result in a mosaic pattern in the affected lesion [5]. Therefore, molecular testing of peripheral blood or saliva has been ineffective for detecting pathogenic variants in patients with PROS [3]. Meanwhile, archival formalin-fixed paraffin-embedded (FFPE) tissues can be a valuable resource for clinical genomic studies [18], but the DNA obtained from these tissues can have a wide range of quality depending on factors such as age, DNA–protein crosslinking, fixation conditions, and inhibitors, all of which can affect downstream genomic analyses [19].

Next-generation sequencing (NGS) involving an amplicon-based targeted sequencing method with high sensitivity can identify low-level mosaicism from low-input DNA extracted from FFPE tissues and provide a diagnostic option when affected tissue is available [20]. Therefore, this study aimed to demonstrate the clinical utility of targeted NGS with a custom-designed panel for identifying PIK3CA mosaicism in archival FFPE tissues from patients with KTS, a relatively rare vascular malformation with limb hypertrophy.

Results

Patient characteristics

Participants were 9 female and 5 male patients, including 5 (35.7%) adults (defined as age 18 years or older). Their clinical characteristics and genetic profiles are shown in Table 1. Median age at resection was 14 years (range, 5–57 years). Archival median period before DNA extraction from FFPE tissues was 5.4 years (range, 3–7 years). Lesions were resected from the abdomen (n = 2), buttock (n = 1), thigh (n = 2), knee (n = 3), lower leg (n = 4), and foot (n = 2). Tissue specimens were skin with subcutaneous tissue (n = 8), subcutaneous tissue only (n = 5), and subcutaneous tissue with muscles (n = 1). Figure 1 shows clinical photographs and magnetic resonance imaging (MRI) of all patients with detected PIK3CA variants. Patient 1 [21], patients 3 and 4 [22], and patient 9 [23] were previously reported without genetic analyses.

Table 1 Summary of clinical manifestations and identified PIK3CA variants in patients with Klippel–Trenaunay syndrome
Full size table
Fig. 1
figure 1

Clinical photographs (upper) and short-tau inversion recovery or fat-suppressed T2-weighted magnetic resonance images (lower) of the patients with Klippel–Trenaunay syndrome with detected or undetected PIK3CA variants. Various clinical manifestations were observed, including geographic capillary malformations (a, c-g, i, l), lower limb discrepancy in terms of length (c, d, f, g, i, l, m), and macrodactyly (a, c, d, f, l). Magnetic resonance images are axial views at the arrowhead position in each clinical photograph with the lesions of high signal intensity

Full size image

Clinicopathological diagnoses were capillaro-venous malformation (CVM) (n = 8) and capillaro-lymphatico-venous malformation (CLVM) (n = 6). Geographic CMs were found in 8 patients. Lower limb discrepancy (LLD) in terms of length was found in 7 patients, including 2 patients with epiphysiodesis, while LLD in terms of girth was observed in all 14 patients (right-sided hypertrophy in 7 patients). Digital anomalies were found in 5 patients as macrodactyly of the foot. Patient 7 had bilateral lesions in the lower limbs (with CLVM in the left limb) and bilateral macrodactyly, and the longer right limb required epiphysiodesis. Thirteen patients had received treatment prior to resection for genetic analysis, including partial resection (n = 10), percutaneous sclerotherapy (n = 12), transcatheter arterial embolization for micro-arteriovenous shunts (n = 6), and high ligation of a lateral marginal vein in the thigh (n = 4).

Detection of PIK3CA variants

Median DNA concentration from FFPE tissues measured using a Qubit 3.0 Fluorometer and a 2200 TapeStation system were respectively 20.5 ng/µL and 25.5 ng/µL. NGS-based ultradeep sequencing of PIK3CA achieved an amplicon mean coverage of 119,000x (range, 96,000–142,000x) for FFPE tissues and 107,000x (range, 95,000–136,000x) for controls.

The detected PIK3CA variant frequency in positive control DNA of 5%, 1%, 0.5%, and 0.1% of E545K/ H1047R mixture were respectively 4.3%, 0.8%, 0.5%, and 0.1% in E545K and 10.3%, 1.2%, 0.5%, and 0.1% in H1047R. No PIK3CA variants were detected in negative control DNA. PIK3CA missense mutations were found in 12 of 14 patients (85.7%; 6/8 CVM and 6/6 CLVM) (Table 1). Of the 12 variants detected, 8 (66.7%) were hotspot variants: E542K (c.1624G > A) in 2 patients, E545K (c.1633G > A) in 2, H1047R (c.3140 A > G) in 3, and H1047L (c.3140 A > T) in 1. The rest were 3 distinct non-hotspot variants: C420R (c.1258T > C) in 1 patient, Q546R (c.1637 A > G) in 2, and Q546K (c.1636 C > A) in 1. All of the detected PIK3CA variants were previously reported in patients with PROS or LM and are considered pathogenic variants according to ClinVar (Table 2). Overall, the mean variant allele frequency (VAF) for the identified PIK3CA variants was 6.9% (range, 1.6–17.4%). Summaries of the PIK3CA variants in PROS (n = 696) [3, 6,7,8, 20, 24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48] and vascular malformations except PORS (including LM, VM, fibro-adipose vascular anomaly and combined vascular malformations; n = 307) [6, 8, 42, 49,50,51,52,53,54,55] from the literature as well as our cohort (n = 12) are presented in Additional file 1, Fig. 2 (frequent variants in PROS ≥ 5 patients in each variant, n = 597 from the literature; vascular malformations except PORS, n = 300), and Table 2 (variants presented in Fig. 2), including the ranks in COSMIC v97 and variant class in ClinVar.

Table 2 Summary of the frequent PIK3CA variants found in PROS and vascular malformations
Full size table
Fig. 2
figure 2

Distribution of frequent PIK3CA variants in PIK3CA-related overgrowth spectrum (PROS) [3, 6,7,8, 20, 24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48] and vascular malformations [6, 8, 42, 49,50,51,52,53,54,55] from the literature as well as our cohort (variants in PROS ≥ 5 patients in each variant). Right, variants found in patients with PROS (blue, n = 597) in the literature and Klippel–Trenaunay syndrome (KTS) in our cohort (orange, n = 12). Left, variants found in patients with vascular malformations except PROS (green, n = 300) in the literature. ABD, p85α-binding domain; RBD, Ras-binding domain; C2, C2 domain; Helical, helical domain; Kinase, kinase domain

Full size image

Genotype–phenotype analysis

All patients with geographic CM, histopathological LM, or macrodactyly of the foot had PIK3CA variants. However, we did not find any association with phenotype or its severity between hotspot and non-hotspot PIK3CA variants.

Histopathological analysis

The expression of D2-40 in lymphatic endothelial cells was confirmed in 6 patients. Anastomosing vascular channels were found in all 14 patients with positive stains for p-AKT (n = 12), p-mTOR (n = 7), and p-4EBP1 (n = 14); small vessels were found in 11 patients with positive stains for p-AKT (n = 10), p-mTOR (n = 1), and p-4EBP1 (n = 11); venules were found in all 14 patients with positive stains for p-AKT (n = 14), p-mTOR (n = 10), and p-4EBP1 (n = 14); and adipose tissues were found in all 14 patients with positive stains for p-AKT (n = 8), p-mTOR (n = 1), and p-4EBP1 (n = 12). Positive stains for p-AKT, p-mTOR, and p-4EBP1 were also found in two patients with undetected PIK3CA variants in vessels and adipose tissues. Representative images of hematoxylin and eosin, p-AKT, p-mTOR, and p-4EBP1 stains are shown in Fig. 3. The immunohistochemical analysis results for all patients are shown in Table 3.

Fig. 3
figure 3

Histology and immunohistochemical analysis of the PI3K/AKT/mTOR signaling pathway in the serial sections of patients with Klippel–Trenaunay syndrome. Representative images of anastomosing vascular channels (a-d), small vessels (0.1–1.0 mm diameter) (e-h), venules (10–100 μm diameter) (i-l), and adipose tissues (m-p). Staining for hematoxylin and eosin (HE) (a, e, i, m), p-AKT (b, f, j, n), p-mTOR (c, g, k, o), and p-4EBP1 (d, h, l, p). Cytoplasmic intensity of the immunohistochemical stains graded as positive (b, d, f, h, j, k, l, n, p) and negative (c, g, o). Scale bars: a-d, m-p = 250 μm, e-h = 100 μm, i-l = 50 μm

Full size image
Table 3 Immunohistochemical analysis of the lymphatic endothelial marker D2-40 and the PI3K/AKT/mTOR signaling pathway
Full size table

Discussion

This study investigated the largest cohort of molecularly diagnosed patients with KTS in an Asian population. Using archival FFPE tissues, we identified PIK3CA variants in 85.7% of our cohort with KTS, 66.6% of which were the hotspot variants E542K, E545K, H1047R, and H1047L. The non-hotspot variants Q546K and Q546R were also identified, despite being rare in patients with vascular malformations. To our knowledge, Q546K was previously unreported in patients with KTS but was found in a patient with a fibro-adipose vascular anomaly [6] and in 3 patients with LM [8, 52]. Q546R has been reported in a patient with KTS [7] as well as a patient with LM [8] (Fig. 2). Our mutational findings were in line with those of patients with KTS in Western populations [3, 6, 8].

The PI3K catalytic subunit p110α encoded by PIK3CA has five domains: a C2 domain, a helical domain, a kinase domain, an N-terminal adapter-binding domain, and a Ras-binding domain (Fig. 2) [56]. In many cancers, mutations are found throughout the entire p110α protein, except for the Ras-binding domain, including the following hotspots: E542 and E545 in the helical domain and H1047 in the kinase domain [17]. The PIK3CA variants in PROS, including KTS, have a similar profile to that in cancers (Table 2), and an association of hotspot variants with more severe hypertrophy has been suggested, with milder hypertrophy linked to rarer non-hotspot variants [7, 27, 30]. However, in our cohort, patients who had non-hotspot variants did not exhibit milder hypertrophy compared with those who had hotspot variants. Thus, a meta-analysis should be conducted to clarify any potential genotype–phenotype correlations in this rare disease. To that end, molecular diagnoses may prove helpful in providing prognostic information on clinical manifestations [20].

Molecular genetic testing for the diagnosis of PROS requires clinically affected tissues, preferably fresh frozen tissues [4]. Testing can be performed using FFPE tissues; however, unlike fresh frozen tissues, DNA obtained from FFPE tissues can vary widely in terms of quality [19]. NGS with the use of a highly sensitive amplicon-based targeted sequencing method can identify low-level mosaicism from DNA extracted from widely available archival FFPE tissues [20]. Although digital droplet PCR is a simple and highly sensitive and specific method for the detection and quantification of targeted DNA variants, entire exons must be sequenced by NGS in order to capture all the coding single-nucleotide variants as well as small insertion and deletion variants in rare diseases [4]. Detection of rare variants remains a challenge because of the error-prone nucleotide changes resulting from sequencing errors. NGS combined with molecular barcodes can eliminate false-positive variants and enable detection thresholds of 0.1% VAF [57].

Using archival FFPE tissues, we were able to compare the genotype and histology of the lesions. Immunohistochemistry revealed that the vessels in all 14 patients and the adipose tissues in 13 patients expressed p-AKT, p-mTOR, and/or p-4EBP1 (Fig. 3; Table 3), indicating enhanced activation of the PI3K/AKT/mTOR pathway in mesenchymal tissues compared with that in normal tissues in these patients with KTS. These findings are in line with previous reports of PIK3CA variants detected in adipocytes in PROS [3] and abnormal vessels detected in fibro-adipose vascular anomaly [58]. However, 2 patients (patients 13 and 14) with undetected PIK3CA variants showed some expression of p-AKT, p-mTOR, and/or p-4EBP1 in vessels and adipose tissues. Neither had geographic CM, histopathological LM, or macrodactyly of the foot. Patient 13 can be diagnosed with CVM and congenital nonprogressive limb overgrowth [59] caused by somatic GNA11 mutation [60]. Patient 14 might have common VM caused by a somatic TEK mutation [61] encoding TIE2 upstream of the PI3K/AKT/mTOR pathway.

To date, fewer than 30 different PIK3CA gene variants have been reported in PROS, five of which—C420R, E542K, E545K, H1047R, and H1047L—have been shown to be recurrent [5]. As for the PIK3CA variants in patients with KTS [3, 6,7,8,9], Kurek et al. reported H1047R in 3 of 15 patients [3], while Luks et al. reported E542K in 3, E545K in 9, E545G in 1, H1047R in 6, and H1047L in 1 of 21 patients [6]. Kuentz et al. reported G364R in 1, E542K in 1, E545K in 2, Q546R in 1, and H1047L in 1 of 13 patients [7]. Brouillard et al. reported E110del in 1, and E545K in 3 of 4 patients [8]. Nozawa et al. reported E542K in 2, E545K in 5, and H1047R in 1 of 10 patients [9].

The therascreen® PIK3CA RGQ PCR Kit was developed to be a companion diagnostic tool for 11 PIK3CA gene variants: C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y. It uses genomic DNA extracted from FFPE or circulating tumor DNA isolated from plasma in patients with breast cancer. Patients with advanced or metastatic breast cancer who test positive for the presence of one or more PIK3CA variants are eligible for treatment with the PI3K inhibitor alpelisib [62]. With a limit of detection from 2.4 to 14.04% VAF [63], the therascreen kit would not have detected five cases in our cohort because of the low VAF (C420R with 1.6% VAF; E542K with 3.3% VAF; Q546R with 3.9% VAF and 5.9% VAF, respectively; and H1047R with 1.6% VAF) as well as one case with the Q546K variant, which is not targeted by the kit.

Our findings have potential implications for the treatment of patients with KTS using inhibitors of the PI3K/AKT/mTOR signaling pathway, which have shown promising results with mTOR inhibitor sirolimus [64, 65], pan-AKT inhibitor miransertib [66], and selective class I PI3K inhibitor alpelisib [67] or taselisib [68]. It is thus critical to obtain more detailed information regarding specific variants in order to identify of the options for targeted treatment [69].

This study has some limitations. First, we evaluated only patients with KTS who were diagnosed based on the triad of CM, VM, and hypertrophy of the affected limb [2], so there was no controlling for vascular malformations except KTS in the immunohistochemical analysis. Second, we performed targeted sequencing of PIK3CA gene coding sequences using a panel consisting of amplicons with an overall coverage of 87.9%, so genes not on the panel would have been missed.

Conclusions

We identified PIK3CA variants in 12 of 14 patients (85.7%) with KTS by using archival FFPE tissues, and 8 of these patients had the following hotspot variants: E542K, E545K, H1047R, and H1047L. The rarer non-hotspot PIK3CA variants Q546R and Q546K were also identified in 3 patients. Amplicon-based targeted NGS was able to identify low-level mosaicism from low-input DNA extracted from FFPE tissues, suggesting its potential as a diagnostic option for personalized medicine.

Methods

Patients

This retrospective study involved Japanese patients with vascular malformations with lower limb hypertrophy who underwent resection of the vascular malformations at Tonan Hospital between 2011 and 2020. Of the 17 patients identified, 14 provided written informed consent and were included in the analysis. KTS was diagnosed based upon the triad of CM, VM, and hypertrophy of the affected limb [2]. In younger patients, VM was often less conspicuous but was diagnosed based on veins that were subtly dilated relative to the unaffected limb [70].

The patients’ medical charts were reviewed, and the following demographic information and medical history data were collected: sex, date and age at resection, lesion resected, type of tissues in resected specimens, clinical photographs, and radiologic studies. Geographic CMs were defined as those with sharply demarcated borders and saturated dark red/purple color throughout the entire stain [70].

Prior to resection, all patients underwent MRI and color duplex ultrasound to evaluate the characteristics, distribution, and extent of the lesions. Vascular malformations were diagnosed based on the clinical history as well as the physical examination, ultrasonography, and MRI findings. LLD was evaluated in terms of length and girth according to teleoroentgenography and cross-section on MRI, respectively. LLD in terms of length was defined as 5 mm longer compared with the unaffected limb in children and 1 cm longer in adults, while LLD in terms of girth was defined as 10% greater in cross-sectional area compared with the unaffected limb [71].

DNA extraction

Surgical specimens were fixed with 10% buffered formalin and embedded in paraffin. Affected tissue was retrieved from archived FFPE tissue blocks. QIAamp DNA FFPE Tissue Kit (Qiagen, Germantown, MD) was used to extract genomic DNA from FFPE tissues. The positive and negative control DNA from the FFPE PIK3CA Reference Standard (E545K, HD112; H1047R, HD599; wild-type [WT], HD320; Horizon Discovery, Cambridge, UK) were extracted using a Maxwell RSC FFPE DNA Kit (Promega, Madison, WI). The concentration and quality of the extracted DNA were assessed using a 2200 TapeStation system with the Genomic DNA ScreenTape (Agilent, Santa Clara, CA) and a Qubit 3.0 Fluorometer with a Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific, Waltham, MA), respectively. DNA controls were prepared for each condition: 5%, 1%, 0.5% and 0.1% of E545K/ H1047R mixture diluted in WT for the positive controls and only WT for the negative control.

Next-generation sequencing

We used an Ion AmpliSeq™ HD Made-to-Order Panel (IAH215884_374) to perform targeted sequencing of all PIK3CA gene coding sequences (3,607 bp). The panel consisted of 64 amplicons with an overall coverage of 87.9%. Deaminated cytosine residues were removed from 20 ng of the sample DNA and the target region was amplified using multiplex PCR with the Ion AmpliSeq™ HD Library Kit (Thermo Fisher Scientific). The primer sequence in the amplicon was partially digested, and the library was amplified using primers, to which barcode sequences were added using Ion AmpliSeq™ HD Dual Barcode Kit (Thermo Fisher Scientific). After purification of the library DNA, the concentration and size of DNA were checked, and the library was mixed. Emulsion PCR was performed to clonally amplify the library DNA on beads and then template beads were collected and sequencing reactions were performed on the Ion S5™ XL system (Thermo Fisher Scientific) using an Ion Chef 550 Chip Kit (Thermo Fisher Scientific).

Bioinformatics analysis for detection of PIK3CA variant

The quality of the read data was checked, and the adapter sequences and poor-quality reads were removed. Then, the reads were mapped to reference sequences (hg19) using the torrent mapping alignment program of Torrent Suite ver. 5.16.1(Thermo Fisher Scientific) and variants were detected using Ion Reporter ver. 5.18 (Thermo Fisher Scientific). Annotation information was assigned to the detected variants. The thresholds for the main parameters of Ion Reporter’s variant detection were set as follows: Downsample to Coverage: 20,000; Minimum Allele Frequency of SNP (single nucleotide polymorphism), MNP (multiple nucleotide polymorphism), and INDEL (insertion or deletion of nucleotides): 0.05%; Minimum Variant Score of SNP and MNP: 6; Minimum Variant Score of INDEL: 10.

Histology and immunohistochemistry

The serial FFPE Sect. (5 μm thick) were stained using immunohistochemical as well as hematoxylin and eosin stains for a lymphatic endothelial marker D2-40 (#916,606, 1:1,000, BioLegend, San Diego, CA), p-AKT (#4060, 1:75; Cell Signaling Technology, Danvers, MA), p-mTOR (#2976, 1:100; Cell Signaling Technology), and p-4EBP1 (#2855, 1:200; Cell Signaling Technology). The expression of D2-40 in endothelial cells was used to diagnose LM. Vessels were categorized into three groups according to type and/or size: anastomosing vascular channels [72], small vessels (0.1–1.0 mm diameter), and venules (10–100 μm diameter). Vessels and adipose tissues were evaluated in terms of the cytoplasmic intensity of immunohistochemical stains graded as positive or negative by two independent observers. The connective tissues surrounding the lesions were used as a control.

Data Availability

The datasets generated and analyzed during this study are available from the corresponding author upon reasonable request.

Change history

  • 13 February 2024

    Incorrectly added sentence under the title that had to be deleted during proofing and editing: List the full names and institutional addresses for all authors. Also, table 1 “Patient” column had to be made more narrow to widen the last “Previous treatments” column, not to make line breaking in the last column. Moreover, table 3 “Patient” column had to be made more narrow.

Abbreviations

CM:

capillary malformation

CVM:

capillaro-venous malformation

CLVM:

capillaro-lymphatico-venous malformation

4EBP1:

eukaryotic translation initiation factor 4E-binding protein 1

FFPE:

formalin-fixed paraffin-embedded

KTS:

Klippel–Trenaunay syndrome

LLD:

lower limb discrepancy

LM:

lymphatic malformation

MRI:

magnetic resonance imaging

mTOR:

mammalian target of rapamycin

NGS:

next-generation sequencing

PI3K:

phosphatidylinositol 3-kinase

PROS:

PIK3CA-related overgrowth spectrum

VAF:

variant allele frequency

VM:

venous malformation

WT:

wild-type

References

  1. Klippel M, Trenaunay P. Memoires originaux: du naevus variqueux osteo-hypertrophique. Arch Gen Med (Paris). 1900;3:641–72.

    Google Scholar 

  2. ISSVA Classification of Vascular Anomalies. ©2018 International Society for the study of vascular anomalies available at issva.org/classification Accessed April 10, 2023.

  3. Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet. 2012;90:1108–15. https://doi.org/10.1016/j.ajhg.2012.05.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet Part A. 2015;167A:287–95. https://doi.org/10.1002/ajmg.a.36836.

    Article  CAS  PubMed  Google Scholar 

  5. Vahidnezhad H, Youssefian L, Uitto J. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS). Exp Dermatol. 2016;25:17–9. https://doi.org/10.1111/exd.12826.

    Article  CAS  PubMed  Google Scholar 

  6. Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovee JV, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr. 2015;166:1048–54. https://doi.org/10.1016/j.jpeds.2014.12.069. e1-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kuentz P, St-Onge J, Duffourd Y, Courcet JB, Carmignac V, Jouan T, et al. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genet Med. 2017;19:989–97. https://doi.org/10.1038/gim.2016.220.

    Article  CAS  PubMed  Google Scholar 

  8. Brouillard P, Schlögel MJ, Homayun Sepehr N, Helaers R, Queisser A, Fastré E, et al. Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations. Orphanet J Rare Dis. 2021;16:267. https://doi.org/10.1186/s13023-021-01898-y.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Nozawa A, Fujino A, Yuzuriha S, Suenobu S, Kato A, Shimizu F, et al. Comprehensive targeted next-generation sequencing in patients with slow-flow vascular malformations. J Hum Genet. 2022;67:721–8. https://doi.org/10.1038/s10038-022-01081-6.

    Article  PubMed  Google Scholar 

  10. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3:1221–4. https://doi.org/10.4161/cc.3.10.1164.

    Article  CAS  PubMed  Google Scholar 

  11. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, et al. Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature. 2008;453:662–6. https://doi.org/10.1038/nature06892.

    Article  CAS  PubMed  ADS  Google Scholar 

  12. Castillo SD, Baselga E, Graupera M. PIK3CA mutations in vascular malformations. Curr Opin Hematol. 2019;26:170–8. https://doi.org/10.1097/MOH.0000000000000496.

    Article  CAS  PubMed  Google Scholar 

  13. Stanczuk L, Martinez-Corral I, Ulvmar MH, Zhang Y, Lavina B, Fruttiger M, et al. cKit lineage hemogenic endothelium-derived cells contribute to mesenteric lymphatic vessels. Cell Rep. 2015;10:1708–21. https://doi.org/10.1016/j.celrep.2015.02.026.

    Article  CAS  PubMed  Google Scholar 

  14. Brouillard P, Boon L, Vikkula M. Genetics of lymphatic anomalies. J Clin Invest. 2014;124:898–904. https://doi.org/10.1172/JCI71614.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Vahidnezhad H, Youssefian L, Uitto J. Molecular genetics of the PI3K-AKT-mTOR pathway in genodermatoses: diagnostic implications and treatment opportunities. J Invest Dermatol. 2016;136:15–23. https://doi.org/10.1038/JID.2015.331.

    Article  CAS  PubMed  Google Scholar 

  16. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554. https://doi.org/10.1126/science.1096502.

    Article  CAS  PubMed  Google Scholar 

  17. Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol Med. 2018;24. https://doi.org/10.1016/j.molmed.2018.08.003. :856 – 70.

  18. McDonough SJ, Bhagwate A, Sun Z, Wang C, Zschunke M, Gorman JA, et al. Use of FFPE-derived DNA in next generation sequencing: DNA extraction methods. PLoS ONE. 2019;14:e0211400. https://doi.org/10.1371/journal.pone.0211400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Do H, Dobrovic A. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem. 2015;61:64–71. https://doi.org/10.1373/clinchem.2014.223040.

    Article  CAS  PubMed  Google Scholar 

  20. Quindipan C, Cotter JA, Ji J, Mitchell WG, Moke DJ, Navid F, et al. Custom pediatric oncology next-generation sequencing panel identifies somatic mosaicism in archival tissue and enhances targeted clinical care. Pediatr Neurol. 2020;114:55–9. https://doi.org/10.1016/j.pediatrneurol.2020.09.015.

    Article  PubMed  Google Scholar 

  21. Ishikawa K, Funayama E, Yamamoto Y, Furukawa H, Hayashi T, Murao N, et al. Squamous cell carcinoma arising in a chronic leg ulcer in Klippel-Trenaunay syndrome after the Charles procedure: a case with 40 years of follow up. J Dermatol. 2019;46:e403–e5. https://doi.org/10.1111/1346-8138.15001.

    Article  PubMed  Google Scholar 

  22. Ishikawa K, Yamamoto Y, Funayama E, Furukawa H, Sasaki S. Wound-healing problems associated with combined vascular malformations in Klippel-Trenaunay syndrome. Adv Wound Care (New Rochelle). 2019;8:246–55. https://doi.org/10.1089/wound.2018.0835.

    Article  PubMed  Google Scholar 

  23. Saito N, Sasaki S, Shimizu T, Nagao M, Fujita M, Nishioka N, et al. [Venous malformations of the lower limb: a review of 110 cases]. Japanese J Plast Surg. 2015;58:679–86. in Japanese.

    Google Scholar 

  24. Lindhurst MJ, Parker VE, Payne F, Sapp JC, Rudge S, Harris J, et al. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet. 2012;44:928–33. https://doi.org/10.1038/ng.2332.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Rivière JB, Mirzaa GM, O’Roak BJ, Beddaoui M, Alcantara D, Conway RL, et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet. 2012;44:934–40. https://doi.org/10.1038/ng.2331.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Rios JJ, Paria N, Burns DK, Israel BA, Cornelia R, Wise CA, et al. Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. Hum Mol Genet. 2013;22:444–51. https://doi.org/10.1093/hmg/dds440.

    Article  CAS  PubMed  Google Scholar 

  27. Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Parker VE, Blumhorst C, Darling T, et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet Part A. 2014;164A:1713–33. https://doi.org/10.1002/ajmg.a.36552.

    Article  CAS  PubMed  Google Scholar 

  28. Maclellan RA, Luks VL, Vivero MP, Mulliken JB, Zurakowski D, Padwa BL, et al. PIK3CA activating mutations in facial infiltrating lipomatosis. Plast Reconstr Surg. 2014;133:12e–9. https://doi.org/10.1097/01.prs.0000436822.26709.7c. e.

    Article  CAS  PubMed  Google Scholar 

  29. Loconte DC, Grossi V, Bozzao C, Forte G, Bagnulo R, Stella A, et al. Molecular and functional characterization of three different postzygotic mutations in PIK3CA-related overgrowth spectrum (PROS) patients: Effects on PI3K/AKT/mTOR signaling and sensitivity to PIK3 inhibitors. PLoS ONE. 2015;10:e0123092. https://doi.org/10.1371/journal.pone.0123092.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Mirzaa G, Timms AE, Conti V, Boyle EA, Girisha KM, Martin B, et al. PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. JCI Insight. 2016;1. https://doi.org/10.1172/jci.insight.87623.

  31. Chang F, Liu L, Fang E, Zhang G, Chen T, Cao K, et al. Molecular diagnosis of mosaic overgrowth syndromes using a custom-designed next-generation sequencing panel. J Mol Diagn. 2017;19:613–24. https://doi.org/10.1016/j.jmoldx.2017.04.006.

    Article  CAS  PubMed  Google Scholar 

  32. Hucthagowder V, Shenoy A, Corliss M, Vigh-Conrad KA, Storer C, Grange DK, et al. Utility of clinical high-depth next generation sequencing for somatic variant detection in the PIK3CA-related overgrowth spectrum. Clin Genet. 2017;91:79–85. https://doi.org/10.1111/cge.12819.

    Article  CAS  PubMed  Google Scholar 

  33. Leiter SM, Parker VER, Welters A, Knox R, Rocha N, Clark G, et al. Hypoinsulinaemic, hypoketotic hypoglycaemia due to mosaic genetic activation of PI3-kinase. Eur J Endocrinol. 2017;177:175–86. https://doi.org/10.1530/EJE-17-0132.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Yeung KS, Ip JJ, Chow CP, Kuong EY, Tam PK, Chan GC, et al. Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum. Am J Med Genet Part A. 2017;173:978–84. https://doi.org/10.1002/ajmg.a.38105.

    Article  CAS  PubMed  Google Scholar 

  35. Michel ME, Konczyk DJ, Yeung KS, Murillo R, Vivero MP, Hall AM, et al. Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum. Clin Genet. 2018;93:1075–80. https://doi.org/10.1111/cge.13195.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Piacitelli AM, Jensen DM, Brandling-Bennett H, Gray MM, Batra M, Gust J, et al. Characterization of a severe case of PIK3CA-related overgrowth at autopsy by droplet digital polymerase chain reaction and report of PIK3CA sequencing in 22 patients. Am J Med Genet Part A. 2018;176:2301–8. https://doi.org/10.1002/ajmg.a.40487.

    Article  CAS  PubMed  Google Scholar 

  37. Siegel DH, Cottrell CE, Streicher JL, Schilter KF, Basel DG, Baselga E, et al. Analyzing the genetic spectrum of vascular anomalies with overgrowth via cancer genomics. J Invest Dermatol. 2018;138:957–67. https://doi.org/10.1016/j.jid.2017.10.033.

    Article  CAS  PubMed  Google Scholar 

  38. Wu J, Tian W, Tian G, Sumner K, Hutchinson DT, Ji Y. An investigation of PIK3CA mutations in isolated macrodactyly. J Hand Surg Eur Vol. 2018;43:756–60. https://doi.org/10.1177/1753193418770366.

    Article  PubMed  Google Scholar 

  39. Lalonde E, Ebrahimzadeh J, Rafferty K, Richards-Yutz J, Grant R, Toorens E, et al. Molecular diagnosis of somatic overgrowth conditions: a single-center experience. Mol Genet Genomic Med. 2019;7:e536. https://doi.org/10.1002/mgg3.536.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Blackburn PR, Milosevic D, Marek T, Folpe AL, Howe BM, Spinner RJ, et al. PIK3CA mutations in lipomatosis of nerve with or without nerve territory overgrowth. Mod Pathol. 2020;33:420–30. https://doi.org/10.1038/s41379-019-0354-1.

    Article  CAS  PubMed  Google Scholar 

  41. Davis S, Ware MA, Zeiger J, Deardorff MA, Grand K, Grimberg A et al. Growth hormone deficiency in megalencephaly-capillary malformation syndrome: an association with activating mutations in PIK3CA. American journal of medical genetics part A. 2020;182:162–8. https://doi.org/10.1002/ajmg.a.61403.

  42. Le Cras TD, Goines J, Lakes N, Pastura P, Hammill AM, Adams DM, et al. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation. Angiogenesis. 2020;23:425–42. https://doi.org/10.1007/s10456-020-09722-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Park HJ, Shin CH, Yoo WJ, Cho TJ, Kim MJ, Seong MW, et al. Detailed analysis of phenotypes and genotypes in megalencephaly-capillary malformation-polymicrogyria syndrome caused by somatic mosaicism of PIK3CA mutations. Orphanet J Rare Dis. 2020;15:205. https://doi.org/10.1186/s13023-020-01480-y.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Tian W, Huang Y, Sun L, Guo Y, Zhao S, Lin M, et al. Phenotypic and genetic spectrum of isolated macrodactyly: somatic mosaicism of PIK3CA and AKT1 oncogenic variants. Orphanet J Rare Dis. 2020;15:288. https://doi.org/10.1186/s13023-020-01572-9.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Garde A, Guibaud L, Goldenberg A, Petit F, Dard R, Roume J, et al. Clinical and neuroimaging findings in 33 patients with MCAP syndrome: a survey to evaluate relevant endpoints for future clinical trials. Clin Genet. 2021;99:650–61. https://doi.org/10.1111/cge.13918.

    Article  CAS  PubMed  Google Scholar 

  46. Palmieri M, Pinto AM, di Blasio L, Curro A, Monica V, Sarno LD, et al. A pilot study of next generation sequencing-liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel-Trenaunay syndrome. Vascular. 2021;29:85–91. https://doi.org/10.1177/1708538120936421.

    Article  CAS  PubMed  Google Scholar 

  47. Gökpinar Ili E, Tasdelen E, Durmaz CD, Altiner S, Tuncali T, Martinez-Glez V, et al. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS). Am J Med Genet Part A. 2022;188:1792–800. https://doi.org/10.1002/ajmg.a.62709.

    Article  CAS  PubMed  Google Scholar 

  48. Mussa A, Leoni C, Iacoviello M, Carli D, Ranieri C, Pantaleo A, et al. Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants. J Med Genet. 2023;60:163–73. https://doi.org/10.1136/jmedgenet-2021-108093.

    Article  CAS  PubMed  Google Scholar 

  49. Boscolo E, Coma S, Luks VL, Greene AK, Klagsbrun M, Warman ML, et al. AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation. Angiogenesis. 2015;18:151–62. https://doi.org/10.1007/s10456-014-9453-2.

    Article  CAS  PubMed  Google Scholar 

  50. Limaye N, Kangas J, Mendola A, Godfraind C, Schlögel MJ, Helaers R, et al. Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet. 2015;97:914–21. https://doi.org/10.1016/j.ajhg.2015.11.011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Ten Broek RW, Eijkelenboom A, van der Vleuten CJM, Kamping EJ, Kets M, Verhoeven BH, et al. Comprehensive molecular and clinicopathological analysis of vascular malformations: a study of 319 cases. Genes Chromosomes Cancer. 2019;58:541–50. https://doi.org/10.1002/gcc.22739.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Zenner K, Cheng CV, Jensen DM, Timms AE, Shivaram G, Bly R, et al. Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations. JCI Insight. 2019;4. https://doi.org/10.1172/jci.insight.129884.

  53. Wang S, Wang W, Zhang X, Gui J, Zhang J, Guo Y, et al. A somatic mutation in PIK3CD unravels a novel candidate gene for lymphatic malformation. Orphanet J Rare Dis. 2021;16:208. https://doi.org/10.1186/s13023-021-01782-9.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Zenner K, Jensen DM, Cook TT, Dmyterko V, Bly RA, Ganti S, et al. Cell-free DNA as a diagnostic analyte for molecular diagnosis of vascular malformations. Genet Med. 2021;23:123–30. https://doi.org/10.1038/s41436-020-00943-8.

    Article  CAS  PubMed  Google Scholar 

  55. Zenner K, Jensen DM, Dmyterko V, Shivaram GM, Myers CT, Paschal CR, et al. Somatic activating BRAF variants cause isolated lymphatic malformations. HGG Adv. 2022;3:100101. https://doi.org/10.1016/j.xhgg.2022.100101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, et al. The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations. Science. 2007;318:1744–8. https://doi.org/10.1126/science.1150799.

    Article  CAS  PubMed  ADS  Google Scholar 

  57. Suppan C, Graf R, Jahn S, Zhou Q, Klocker EV, Bartsch R, et al. Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. Br J Cancer. 2022;126:456–63. https://doi.org/10.1038/s41416-021-01601-9.

    Article  CAS  PubMed  Google Scholar 

  58. Hori Y, Hirose K, Aramaki-Hattori N, Suzuki S, Nakayama R, Inoue M, et al. Fibro-adipose vascular anomaly (FAVA): three case reports with an emphasis on the mammalian target of rapamycin (mTOR) pathway. Diagn Pathol. 2020;15:98. https://doi.org/10.1186/s13000-020-01004-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Uihlein LC, Liang MG, Fishman SJ, Alomari AI, Mulliken JB. Capillary-venous malformation in the lower limb. Pediatr Dermatol. 2013;30:541–8. https://doi.org/10.1111/pde.12186.

    Article  PubMed  Google Scholar 

  60. Couto JA, Ayturk UM, Konczyk DJ, Goss JA, Huang AY, Hann S, et al. A somatic GNA11 mutation is associated with extremity capillary malformation and overgrowth. Angiogenesis. 2017;20:303–6. https://doi.org/10.1007/s10456-016-9538-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet. 2009;41:118–24. https://doi.org/10.1038/ng.272.

    Article  CAS  PubMed  Google Scholar 

  62. Narayan P, Prowell TM, Gao JJ, Fernandes LL, Li E, Jiang X, et al. FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin Cancer Res. 2021;27:1842–9. https://doi.org/10.1158/1078-0432.CCR-20-3652.

    Article  CAS  PubMed  Google Scholar 

  63. therascreen PIK3CA RGQ PCR Kit Instructions for Use (Handbook) Version 1. QIAGEN GmbH. 2019;55 – 6. https://www.qiagen.com/us/resources/resourcedetail?id=2d7ab465-a0e2-4311-8f90-1bea278aa47e&=en. Accessed 19 Dec 2022.

  64. Hammer J, Seront E, Duez S, Dupont S, Van Damme A, Schmitz S, et al. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study. Orphanet J Rare Dis. 2018;13:191. https://doi.org/10.1186/s13023-018-0934-z.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Parker VER, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, De Silva L, et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Genet Med. 2019;21:1189–98. https://doi.org/10.1038/s41436-018-0297-9.

    Article  CAS  PubMed  Google Scholar 

  66. Forde K, Resta N, Ranieri C, Rea D, Kubassova O, Hinton M, et al. Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome. Orphanet J Rare Dis. 2021;16:109. https://doi.org/10.1186/s13023-021-01745-0.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558:540–6. https://doi.org/10.1038/s41586-018-0217-9.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  68. Luu M, Vabres P, Devilliers H, Loffroy R, Phan A, Martin L, et al. Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study. Genet Med. 2021;23:2433–42. https://doi.org/10.1038/s41436-021-01290-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. Orphanet J Rare Dis. 2021;16:306. https://doi.org/10.1186/s13023-021-01929-8.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Maari C, Frieden IJ. Klippel-Trenaunay syndrome: the importance of geographic stains in identifying lymphatic disease and risk of complications. J Am Acad Dermatol. 2004;51:391–8. https://doi.org/10.1016/j.jaad.2003.12.017.

    Article  PubMed  Google Scholar 

  71. Funayama E, Sasaki S, Oyama A, Furukawa H, Hayashi T, Yamamoto Y. How do the type and location of a vascular malformation influence growth in Klippel-Trenaunay syndrome? Plast Reconstr Surg. 2011;127:340–6. https://doi.org/10.1097/PRS.0b013e3181f95b4c.

    Article  CAS  PubMed  Google Scholar 

  72. Enjolras O, Wassef M, Chapot R. Venous malformations (VM). Color Atlas of vascular tumors and vascular malformations, 168–223, Cambridge University Press, New York, 2007.

    Chapter  Google Scholar 

Download references

Acknowledgements

We are grateful to all the patients for their invaluable participation. The authors thank Mayumi Shitamichi and the staff of the Clinical Biobank, Clinical Research and Medical Innovation Center, Hokkaido University Hospital, for technical assistance with the DNA extractions.

Funding

This study was supported in part by JSPS KAKENHI (JP18K16974) and a research grant from the Japan Intractable Diseases (Nanbyo) Research Foundation (2020B03).

Author information

Author notes

  1. Yuki Sasaki and Kosuke Ishikawa have contributed equally to this work.

Authors and Affiliations

  1. Department of Plastic and Reconstructive Surgery, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita‐ku, Sapporo, 060-8638, Japan

    Yuki Sasaki, Kosuke Ishikawa, Takahiro Miura, Taku Maeda, Emi Funayama & Yuhei Yamamoto

  2. Center for Vascular Anomalies, Department of Plastic and Reconstructive Surgery, Tonan Hospital, Hokkaido, Japan

    Yuki Sasaki, Kosuke Ishikawa, Naoki Murao & Satoru Sasaki

  3. Center for Development of Advanced Diagnostics, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Hokkaido, Japan

    Kanako C. Hatanaka & Yutaka Hatanaka

  4. Department of Diagnostic Pathology, Tonan Hospital, Hokkaido, Japan

    Yumiko Oyamada

  5. Department of Diagnostic and Interventional Radiology, Tonan Hospital, Hokkaido, Japan

    Yusuke Sakuhara & Tadashi Shimizu

  6. Research Division of Genome Companion Diagnostics, Hokkaido University Hospital, Hokkaido, Japan

    Tatsuro Saito & Yutaka Hatanaka

  7. Riken Genesis Co., Ltd, Tokyo, Japan

    Tatsuro Saito

  8. Department of Orthopedic Surgery, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan

    Tomohiro Onodera

Authors
  1. Yuki Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kosuke Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kanako C. Hatanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yumiko Oyamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yusuke Sakuhara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tadashi Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tatsuro Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Naoki Murao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomohiro Onodera
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takahiro Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Taku Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Emi Funayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yutaka Hatanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yuhei Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Satoru Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YS and KI analyzed the results and drafted the manuscript. KI and SS designed and coordinated the study. SS, NM, and TO were involved in recruiting patients. KCH and YO performed the histological analyses. YS and TSh performed the radiological analyses. YH and TS performed NGS and interpreted the genomic data. TMi, TM, EF, and YY revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Kosuke Ishikawa.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the institutional review boards of Hokkaido University Hospital (number 016–0314) and Tonan Hospital (number 512) and was conducted in accordance with principles of the Declaration of Helsinki and its later amendments. The patients or their legal guardians gave their informed consent to be included.

Consent for publication

The patients or their legal guardians provided written informed consent for the publication of this study.

Competing interests

The authors declare no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sasaki, Y., Ishikawa, K., Hatanaka, K.C. et al. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel–Trenaunay syndrome in an Asian population. Orphanet J Rare Dis 18, 270 (2023). https://doi.org/10.1186/s13023-023-02893-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13023-023-02893-1

Keywords

Orphanet Journal of Rare Diseases

ISSN: 1750-1172